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IntroductIon
A special unlicensed medicine is one that 
is manufactured without a marketing 
authorisation (MA) from the Medicines and 
Healthcare products Regulatory Agency 
(MHRA). An MA (or product licence) is granted 
by the MHRA only once a medicinal product 
has been proven to be safe and effective. 
Prescribed products that do not hold an 
MA include those prepared on an individual 
basis by ‘special order’ manufacturers (for 
example liquid preparations), products 
classed as ‘food supplements’ (such as 
vitamin D preparations), and medicines that 
are licensed abroad but which do not hold a 
UK MA.1
currEnt GuIdELInES
The MHRA recommends that unlicensed 
medicines should only be used when 
existing licensed medicinal products are not 
appropriate to meet patient needs2 and this 
is also echoed in guidance from the General 
Medical Council.3 An example of this situation 
often arises in paediatric medicine due to 
smaller or unusual doses being required, 
which cannot normally be administered 
using standard solid oral dosage forms. 
Other examples include patients with 
difficulty swallowing solid oral dosage forms 
and patients needing to receive medicines 
through enteral feeding tubes. Medicines 
that have received marketing authorisations 
in countries other than the UK are another 
example of unlicensed medicines that may be 
employed where licensed preparations have 
been unsuccessful or unsuitable.4 Midodrine 
tablets for example, which are licensed in 
the US but not in the UK, may be used 
for the treatment of orthostatic hypotension 
where treatment with fludrocortisone has 
been unsuccessful, or use of a steroid is 
unsuitable for the patient. There is also 
significant prescribing of products classed 
as ‘food supplements’ that do not hold a 
marketing authorisation.5 
IMPLIcAtIonS For PrEScrIBErS
Prescribing and dispensing of unlicensed 
medicines comes with additional professional 
responsibilities for both the prescriber 
and the dispensing pharmacist.6 Without 
a marketing authorisation, there is no MA 
holder to take responsibility for any adverse 
reactions associated with the medicine’s use 
and this means any liability rests with the 
prescriber.7 However, a prescriber will not 
usually know the source of the medicine, 
as this is decided by the pharmacist.6 
Furthermore, the pharmacist does not 
usually have sufficient information to know 
why an unlicensed preparation has been 
prescribed when undertaking any clinical 
checks. Some unlicensed medicines may be 
initiated by secondary care consultants, but 
the prescribing of them continues in general 
practice through the use of protocols and 
information. For example, a recommendation 
to prescribe melatonin solution for a child 
with a sleep–wake disorder using a shared 
care guideline, such as those used by NHS 
Gateshead CCG.8 It is not yet established 
how patients and professionals perceive and 
understand the potential risks associated 
with the use of unlicensed medicines in such 
circumstances.
Without marketing authorisations, 
unlicensed products do not benefit from 
the data generated as part of the licensing 
application process.9 There is no clinical 
trial data to demonstrate safety and efficacy 
of the formulation and there are no stability 
studies to support a clear expiry date.9,10 As 
a result, unlicensed medicines often have 
recommended expiry and storage conditions 
based only on the experience of their 
manufacturers.10 Frequently unlicensed 
medicines come with no detailed patient 
information, which would also ordinarily 
be produced as part of the application for 
an MA.9 
In 2012, the National Patient Safety Agency 
(NPSA) issued a safety alert around the 
use of buccal midazolam11 and highlighted 
132 medication incidents which had been 
reported through the National Reporting 
and Learning Service. Incidents were found 
in relation to prescribing, dispensing, and 
administration of buccal midazolam and 
included three incidents that resulted in 
severe patient harm and five in moderate 
harm. One of the NPSA recommendations 
to minimise the potential risk was to limit 
the prescribing of midazolam to licensed 
formulations where possible.11 Although 
a licensed preparation of midazolam, 
oromucosal, solution has been available 
since October 2011,12 unlicensed midazolam 
10 mg/mL remains on Part VIIIB of the Drug 
Tariff, implying that it is still acceptable to 
the NHS that prescribers use an unlicensed 
formulation.
It is not known if healthcare professionals 
recognise the limitations and risks of using 
unlicensed medicines, whether they employ 
any strategies to minimise any potential 
risks, and how they balance these risks 
against patient need. The quality of any 
information the patient may receive when 
they are prescribed an unlicensed medicine 
is also unknown.
HEALtH EconoMIc IMPAct
Another significant aspect of the use of 
unlicensed medicines is cost. Based on 
data from the top 500 special order items 
in England and Wales from Quarter 1 
2014/2015, the average cost of an unlicensed 
medicine item was £104.47.13 Among the 
cheapest items are colecalciferol 20 000 unit 
capsules with an average price per item 
of £14.42 (43 717 items), and among the 
most expensive are sodium benzoate tablets 
with an average cost of £807.19 per item 
(43 items).13 It should be noted however that 
an ‘item’ in these data include prescriptions 
for all quantities prescribed, therefore 
treatment durations for each prescription 
will affect the average cost incurred. The 
overall average net ingredient cost per 
prescription item for all medicines in 2013 
was £8.37,14 making the average cost of 
unlicensed medicines over twelve times 
more expensive than licensed preparations. 
While the introduction of Part VIIIB of the 
Drug Tariff in November 2011 seems to have 
caused an overall decrease in total spend on 
special unlicensed medicines15 in primary 
care (no data are available for their use in 
secondary care), they remain a significant 
cost burden to the NHS. However, it remains 
to be seen if healthcare professionals view 
this spend as justified. 
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“It is not known if healthcare professionals recognise 
the limitations and risks of using unlicensed 
medicines ...” 
Increasingly, there has been a drive to take 
frequently-used unlicensed formulations 
and create new licensed products. Where 
new products have been introduced, the 
range of unlicensed preparations for that 
product has been removed from the Drug 
Tariff list, in anticipation that patients 
receiving other strengths of unlicensed 
products could be converted to the newly-
available licensed preparations. However, 
this does not seem to be the case. In May 
2012, the unlicensed liquid preparations for 
ramipril were removed from Part VIIIB of 
the Drug Tariff due to the introduction of the 
licensed ramipril 2.5 mg/5 mL oral solution. 
However, in the financial period Quarter 1 
2014/2015, prescribing data report that there 
were still 355 dispensed unlicensed items 
for ramipril, costing the NHS £77 139.75 
when an appropriate licensed oral liquid 
formulation was available. 
In addition, the top 10 unlicensed medicines 
in the prescribing data still include drugs 
for which there are licensed formulations 
available including melatonin, omeprazole, 
and midazolam (Table 1).13 It is still unclear 
why unlicensed medicines continue to be 
prescribed despite an increasing number of 
licensed alternatives.
SundErLAnd ModEL oF PHArMAcISt 
PrActIcE SuPPort
An example of pharmacist intervention is 
in Sunderland, where clinical pharmacists 
provide support to general practices. 
This is delivered through a contract with 
a pharmacist support service paid for by 
Sunderland Clinical Commissioning Group, 
however some practices also opt to pay for 
additional pharmacist support themselves 
and there are examples in other regions 
where pharmacists are employed directly 
by the practice, such as in Cambridge.16 
As part of their work plan in Sunderland, 
pharmacists will use NHS prescribing data 
to identify patients prescribed unlicensed 
medicines and review their therapy. Requests 
for unlicensed medicines, for example, from 
hospital consultants or where care homes 
require liquid forms of medication, are 
referred to a pharmacist who can review and 
recommend appropriate switches. Practice 
pharmacists also liaise with hospital and 
community pharmacists to ensure patients 
are prescribed the most appropriate product 
to meet their clinical needs. 
The potential role of pharmacists and 
their role in supporting appropriate use of 
medicines was highlighted as part of the NHS 
England Clinical Pharmacists in General 
Practice Pilot 17 and included the example 
of ‘sorting out secondary care referrals for 
“specials” ‘ as one of the potential roles for 
practice pharmacists.
WHErE do WE Go FroM HErE?
Despite the issues associated with the use 
of unlicensed medicines, little information 
is available on the views of healthcare 
professionals on their use in practice. Further 
research is required to explore the views of 
prescribers, pharmacists and patients on the 
use of unlicensed medicines across primary 
and secondary care. A review of any existing 
systems or strategies currently employed 
is required to address some of the issues 
associated with unlicensed medicines and to 
enable healthcare providers to understand 
and control their usage.
concLuSIon
Currently, unlicensed medicines are being 
prescribed and used when there are licensed 
alternatives available and these unlicensed 
medicines are often more expensive 
than their licensed counterparts. There 
are guidelines on the use of unlicensed 
medicines from both the medicines 
regulator and the GMC,2,3 which highlight the 
liability of prescribers who choose to supply 
unlicensed medicines.
What is not currently understood are the 
contexts in which unlicensed medicines 
are used, how prescribers use unlicensed 
medicines, what patients know about 
unlicensed medicines, and how pharmacists 
interact with unlicensed medicine requests 
as part of their supply function. Without this 
full understanding, it is difficult to propose 
systems and processes to ensure that 
unlicensed medicines are used appropriately 
and safely by patients, professionals, and the 
wider NHS.
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table 1. commonly-prescribed unlicensed medicines13
  type of unlicensed number of items 
Medicine  medicine  Quarter 1 2015/2016
Colecalciferol 20 000 unit capsulesa Food supplement 17 213
Melatonin 1 mg/1 mL oral solution‘ Special order’ product 10 142
Melatonin 3 mg capsules Non-UK Food supplement 8002
Diltiazem 2% cream ‘Special order’ product 4967
Omeprazole 10 mg/5 mL oral suspension ‘Special order’ product 4751
Midazolam oromucosal solution 10 mg/1 ml ‘Special order’ product 4993
Magnesium glycerophosphate 97.2 mg tablets Food supplement 4303
Midodrine 5 mg tablets Non-UK import 3243
Metolazone 2.5 mg tablets  Discontinued product 2653
Acetylcysteine 600 mg capsules Food supplement 1812
aLicensed product now available
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